Education
About Us
Working with TipRanks
Follow Us
Helix BioPharma (TSE:HBP)
TSX:HBP
HBP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.50 - C$1.34
Previous CloseN/A
Volume518.00
Average Volume (3M)12.12K
Market Cap
C$90.47M
Enterprise ValueC$50.20M
Total Cash (Recent Filing)C$715.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Oct 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding74,155,760
10 Day Avg. Volume14,930
30 Day Avg. Volume12,124
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Helix BioPharma News
HBP FAQ
What was Helix BioPharma’s price range in the past 12 months?
Helix BioPharma lowest stock price was C$0.50 and its highest was C$1.34 in the past 12 months.
What is Helix BioPharma’s market cap?
Helix BioPharma’s market cap is C$90.47M.
When is Helix BioPharma’s upcoming earnings report date?
Helix BioPharma’s upcoming earnings report date is Oct 24, 2025 which is in 69 days.
How were Helix BioPharma’s earnings last quarter?
Helix BioPharma released its earnings results on Jun 16, 2025. The company reported -C$0.029 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.029.
Is Helix BioPharma overvalued?
According to Wall Street analysts Helix BioPharma’s price is currently Overvalued.
Does Helix BioPharma pay dividends?
Helix BioPharma does not currently pay dividends.
What is Helix BioPharma’s EPS estimate?
Helix BioPharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioPharma have?
Helix BioPharma has 74,155,760 shares outstanding.
What happened to Helix BioPharma’s price movement after its last earnings report?
Helix BioPharma reported an EPS of -C$0.029 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Helix BioPharma?
Currently, no hedge funds are holding shares in TSE:HBP
Company Description
Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
Technical Analysis
BriaCell Therapeutics
―
Covalon Technologies
―
Microbix Biosystms
―
NurExone Biologic
―
Defence Therapeutics
―
Ownership Overview
54.79% Insiders
―
Mutual Funds
― Other Institutional Investors
45.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---